Strategic expansion ProAxsis has expanded its office and operational footprint to Randox Science Park in early 2025, signaling a readiness to scale commercial activities, laboratory capacity, and client services. This creates opportunities to target larger pharmaceutical partners and biotech firms nearby with integrated diagnostics and remote monitoring capabilities.

Clinical trial services With a purpose-built Belfast laboratory and involvement in supporting Phase I–III clinical trials, ProAxsis can offer sample analysis and biomarker measurement services to sponsors seeking active protease and inflammatory biomarker data, expanding revenue through CRO-like collaborations.

Remote monitoring potential The NEATstik remote respiratory monitoring tool and Innovate UK funding position ProAxsis in the growing digital health and telemonitoring space, presenting upsell opportunities to pharma companies and payers aiming to monitor patient cohorts and reduce exacerbations in COPD and related diseases.

Strategic partnerships Recent COPD Foundation collaboration and ongoing pharma-academia client base indicate strong opportunities to co-develop or co-market protease biomarkers and panels, facilitating access to larger networks and joint funding applications.

Product fit and upsell Current CE Marked assays for NE and Proteinase 3, plus expertise in IL-6, IL-8, and TNF-alpha measurement, position ProAxsis to upsell expanded biomarker panels to pharmaceutical and academic customers seeking comprehensive inflammatory profiling for respiratory and related diseases.